Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal

Fineline Cube Jan 15, 2026
Company Deals

Jiangsu Aidea Raises RMB 185 M via Private Placement to Boost Nanda Pharma Stake to 73.4%

Fineline Cube Jan 15, 2026
Company Deals

Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T‑Cell Isolation in Cell Therapy

Fineline Cube Jan 15, 2026
Company Deals

WuXi Biologics Licenses Clinical‑Stage T‑Cell Engager to Zai Lab for Solid Tumor Development

Fineline Cube Jan 15, 2026
Company Deals

WuXi XDC Acquires TOT Bio in $357M Deal to Bolster ADC CDMO Leadership

Fineline Cube Jan 15, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Huadong Medicine’s DR10624 Wins FDA Nod for MASLD Study, First Triple Agonist to Enter Clinic

Fineline Cube Jan 15, 2026
Company Drug

Ipsen’s IPN60340 Wins FDA Breakthrough Therapy Designation for First‑Line AML in Combination

Fineline Cube Jan 15, 2026
Company Drug

BeiGene Receives NMPA Greenlight for BG-C9074 Clinical Trial in Advanced Solid Tumors

Fineline Cube Jul 16, 2024

BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced that the National Medical Products Administration...

Company Drug

Celling Biotechnology’s CEL001 Earns Tacit Approval for Clinical Trials in China

Fineline Cube Jul 16, 2024

Celling Biotechnology Co., Ltd, a Guangzhou-based biopharmaceutical company, has announced that its pipeline candidate CEL001...

Company Drug

Sino Biopharmaceutical’s Rovadicitinib Gets CDE Nod for Review in Myelofibrosis

Fineline Cube Jul 16, 2024

Sino Biopharmaceutical Ltd (HKG: 1177) has announced that the Center for Drug Evaluation (CDE) in...

Company Drug

Sichuan Huiyu’s HY07121 Antifungal Protein Earns NMPA Review for Clinical Trials

Fineline Cube Jul 16, 2024

Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a Chinese biopharmaceutical company, has announced that the...

Company Drug

Betta Pharmaceuticals’ EYP-1901 Implant Secures NMPA Clinical Trial Nod for Wet AMD

Fineline Cube Jul 16, 2024

Betta Pharmaceuticals (SHE: 300558) has announced that it has received clinical trial approval from China’s...

Company Drug

Shenzhen Tyercan Bio-Pharma’s TYE1001 Earns Tacit IND Approval from FDA for Advanced Solid Tumors

Fineline Cube Jul 16, 2024

Shenzhen Tyercan Bio-pharm Co., Ltd, a biopharmaceutical company based in China, has announced that it...

Company Drug

Mabwell Bioscience Receives NMPA Approval for Phase II TNBC Clinical Trial of 9MW2821

Fineline Cube Jul 16, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that China’s National Medical Products Administration...

Company Deals

Lionco Pharmaceutical Partners with Laboratoire Bailly-Creat to Expand Overseas

Fineline Cube Jul 16, 2024

Shanghai-based Lionco Pharmaceutical Group (SHA: 603669) has entered into a strategic partnership framework agreement with...

Company Policy / Regulatory

Novo Nordisk Faces US Senators’ Scrutiny Over Levemir Withdrawal

Fineline Cube Jul 16, 2024

US senators, including Jeanne Shaheen, Raphael Warnock, and Elizabeth Warren, have voiced concerns over Novo...

Company

Johnson & Johnson Appoints Edward Zhou as Medtech China President

Fineline Cube Jul 16, 2024

Johnson & Johnson (J&J, NYSE: JNJ), a global healthcare giant, has announced the appointment of...

Company Drug

Ipsen S.A. Receives NMPA Green Light for Six-Month Diphereline Dosage in Central Precocious Puberty

Fineline Cube Jul 16, 2024

Ipsen S.A. (EPA: IPN; OTCMKTS: IPSEY) has announced that it has received marketing approval from...

Company Drug

Shanghai HeartCare Medical Secures Taiwan Approval for Homegrown Femoral Artery Occluder

Fineline Cube Jul 16, 2024

Shanghai HeartCare Medical Technology Co., Ltd (HKG: 6609), a leading player in the Chinese medical...

Drug Legal / IP Policy / Regulatory

U.S. Senate Passes Affordable Prescriptions for Patients Act to Limit Patent Thicketing

Fineline Cube Jul 15, 2024

In a significant move to curb drug prices, the U.S. Senate unanimously passed the Affordable...

Company Deals

Nona Biosciences Partners with Alaya.bio to Revolutionize CAR-T Therapy Development

Fineline Cube Jul 15, 2024

Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic...

Company Drug

Eisai’s Next-Gen SERD, Orserdu, Begins Real-World Study in Shanghai Ruijin Hospital’s Hainan Subsidiary

Fineline Cube Jul 15, 2024

Shanghai Ruijin Hospital’s Hainan subsidiary has initiated a real-world study for Orserdu (elacestrant), a next-generation...

Company Drug

Everest Medicines’ Velsipity Shows Positive Results in Largest Asian Phase III UC Trial

Fineline Cube Jul 15, 2024

Everest Medicines (HKG: 1952), a leading biopharmaceutical company based in China, has announced positive top-line...

Company Drug

Huadong Medicine’s Partner Arcutis Gets FDA Nod for Roflumilast Cream

Fineline Cube Jul 15, 2024

Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, announced that its co-development partner...

Company Deals Medical Device

Mindray Bio-Medical Partners with Nanjing Municipal Government to Boost Healthcare Innovation

Fineline Cube Jul 15, 2024

Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760), a leading player in the global medical...

Company Deals

Shenzhen-Based National Biological Manufacturing Innovation Center Breaks Ground

Fineline Cube Jul 15, 2024

Construction has commenced on a pioneering national biological manufacturing industry innovation center in Shenzhen, marking...

Company Deals Digital

E-Health Now Secures USD 13.8 Million in Series C Financing to Expand AI Medical Services

Fineline Cube Jul 15, 2024

E-Health Now, a China-based one-stop artificial intelligence (AI)-powered medical health service platform, has reportedly secured...

Posts pagination

1 … 274 275 276 … 610

Recent updates

  • Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal
  • Jiangsu Aidea Raises RMB 185 M via Private Placement to Boost Nanda Pharma Stake to 73.4%
  • Huadong Medicine’s DR10624 Wins FDA Nod for MASLD Study, First Triple Agonist to Enter Clinic
  • Ipsen’s IPN60340 Wins FDA Breakthrough Therapy Designation for First‑Line AML in Combination
  • Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T‑Cell Isolation in Cell Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal

Company Deals

Jiangsu Aidea Raises RMB 185 M via Private Placement to Boost Nanda Pharma Stake to 73.4%

Company Drug

Huadong Medicine’s DR10624 Wins FDA Nod for MASLD Study, First Triple Agonist to Enter Clinic

Company Drug

Ipsen’s IPN60340 Wins FDA Breakthrough Therapy Designation for First‑Line AML in Combination

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.